Professor Sehgal started his scientific career by studying Masters in Animal Genetics and Breeding from National Dairy Research Institute, Karnal where he developed a method to predict the quality attributes of dairy animals by observing sex chromatin.
He pursued M.Phil. in Molecular Biology at university of Poona whereby he demonstrated that in chicken, the messages for eye lens crystalline were present as early as the gastrula stage. After that Dr. Sehgal moved to do his Doctorate in Biochemistry from Indian Agricultural Research Institute, New Delhi where he identified the gene, for neurotoxin synthesis, in wild pea which is responsible for lower limb paralysis. For his Post doctorate, Dr. Sehgal joined University of Maryland, USA where he worked on protein purification.
His second Post Doctorate was at Indian Institute of Science, Bangalore whereby his major accomplishment was to show that caterpillar Bombay mori could be used as Bioreactors for protein synthesis. Further, he was appointed as a Senior Research Scientist in department of Virology at International Centre for Genetic Engineering and Biotechnology, New Delhi. He worked on various aspects of HEV and also found a putative drug combination to reduce genomic load of Hepatitis B virus. He received Welcome Research grant and worked on Drosophila Expression System at University of Sussex (UK).
Professor Sehgal joined Invitrogen (USA) as a group Leader of Protein expression and purification. Subsequently, he joined PanaceaBiotec Ltd. a Biopharmaceutical company where he was group leader and Projects coordinator to develop anti cancer drugs.
He coached the M.Sc. trainees in Molecular Biology to clone various genes into in house designed vectors. Professor Sehgal has a great passion for the innovative research and aptitude for teaching.
Virology: Hepatitis E Virus Culture system and development of the Animal model System
Protein Chemistry: Study the protein processing, structural analysis and their role in replication of HEV.
Drug Development: Biophysical structural analysis of the HEV proteins, Virtual screening and Wet lab validation of the inhibitors as the putative drug candidate